Background: A number of experimental and clinical studies have demonstrated a cardioprotective effect of statins; however, the effect of atorvastatin on cardiac function in patients with an acute myocardial infarction (AMI) has not been established. Methods and results: Thirty consecutive patients with an AMI (16 males and 14 females) were enrolled. All the patients underwent successful percutaneous coronary intervention in the early phase after the onset of an AMI. Patients with a total cholesterol level >200 mg/dL on admission (n = 14) were assigned to the atorvastatin group. They began taking 10 mg of atorvastatin daily within 48 h after the onset of the AMI, while the other patients (n = 16) did not receive atorvastatin and served as the control group. Echocardiography and blood sampling to measure brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) levels were repeated on the 2nd day (2D), 3 weeks (3W), 12 weeks (12W), and 24 weeks (24W) after the onset of the AMI. The percentage of patients with a high BNP level (BNP > 20 pg/mL) was significantly decreased from 2D to 24W in the atorvastatin group, but not in the control group (100 to 57% in the atorvastatin group, p < 0.05; 100 to 80% in the control group, n.s.). Similar results also occurred with respect to the ANP level (ANP > 40 pg/mL) Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction 59 (62 to 21% in the atorvastatin group, p < 0.05; 57 to 40% in the control group, n.s.). The left ventricular ejection fraction was significantly higher in the atorvastatin group than the control group at 3W (66.0 ± 7.8% vs. 56.5 ± 11.8%, p < 0.05) and 24W (67.5 ± 9.2% vs. 59.7 ± 9.8%, p < 0.05). In the atorvastatin group, the left ventricular systolic diameter was significantly decreased at 24W compared with that at 2D (37.1 ± 8.0 mm to 31.4 ± 6.5 mm, p < 0.05). Conclusions: Initiation of atorvastatin in the early phase of an AMI has beneficial effects on cardiac function, probably by improving left ventricular remodeling.
Introduction
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), which are the most effective cholesterol-lowering agents, are attracting much attention because of their pleiotropic effects. A number of clinical trials have been designed to investigate the effects of statins against heart failure by various types of heart diseases. Rosuvastatin reduced the risk of cardiovascular hospitalization in older patients with systolic heart failure [1] . Statin therapy reduced mortality in patients with heart failure [2] [3] [4] [5] , and improved cardiac function in patients with symptomatic dilated cardiomyopathy [6] . These beneficial effects of statins in heart failure are predominantly assumed to be independent of lipid-lowering.
Acute myocardial infarction (AMI) is one of the most serious health issues in developed countries. Primary percutaneous coronary intervention (PCI) is an effective therapy in the acute phase of an AMI, and >70% of patients undergo primary PCI in Japan. In spite of these efforts, heart failure is still a critical complication which determines the prognosis of AMI patients. In the present study, we investigated the effects of early administration of atorvastatin on cardiac function in patients with AMI who underwent primary PCI.
Methods

Study design and patient population
A prospective, non-randomized, single-center clinical trial was conducted involving 30 eligible consecutive patients with AMI who were admitted between May 2004 and March 2006. The protocol was in agreement with the guidelines of the ethics committee in our institution, and written informed consent was obtained from each patient before they were enrolled in the study. An AMI was diagnosed by prolonged chest pain (>30 min), ST elevation in electrocardiography, positive troponine T, and increased serum creatine phosphokinase (>2 times). The patients with severe renal failure, hepatic disease, a previous AMI, and those taking lipid-lowering treatment on admission were excluded.
All the patients underwent successful PCI within 12 h after the onset of the AMI. Patients with a total cholesterol level >200 mg/dL (n = 14) were assigned to the atorvastatin group. They began taking 10 mg atorvastatin daily within 48 h after the AMI onset. The other patients (n = 16) were treated without atorvastatin and served as the control group. Concomitant drugs, except for ticlopidine, that was discontinued 4-8 weeks after reperfusion therapy, were continued during the study period. Echocardiography and blood sampling to measure brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) levels were repeated on the 2nd day (2D), 3 weeks (3W), 12 weeks (12W), and 24 weeks (24W) after the onset of the AMI.
Coronary intervention
PCI was performed in a standard manner with or without stent placement, and succeeded to reperfuse more than TIMI III. After PCI, all patients received aspirin (100 mg) and ticlopidine (100 mg) twice daily for at least 4 weeks.
Statistical analysis
Statistical analysis was performed with Stat View 5.0.1 statistical software (SAS Institute Inc., Cary, NC, USA). Quantitative data are presented as the mean ± S.D. Differences between the two groups were evaluated with Student's t-test in the case of continuous variables and a 2 test in the case of categorical variables. Repeated measurement ANOVA was used to compare the sequential changes of variables during the follow-up between the two groups. Correlations between variables of interest were analyzed using Pearson's correlation coeffi-cient. A p-value<0.05 was considered statistically significant.
Results
Patient characteristics and clinical data
The present study consisted of 30 patients. Fourteen patients comprised the atorvastatin group and 16 patients were in the control group. The clinical characteristics of the patients are shown in Table 1 . The percentage of males and former smoking history were significantly higher in the control group compared with the atorvastatin group (p < 0.05 for each). Other baseline data, including blood pressure, creatinine, glycosylated hemoglobin, and uremic acid levels were not significantly different between the two groups. The culprit artery for the AMI, duration of time from AMI onset-to-admission, the maximum CPK level, and the rate of restenosis investigated at 12W were not significantly different between each group. Concomitant drugs made no significant differences between the two groups ( Table 1) .
Effects on cholesterol and triglyceride levels
The changes in total cholesterol, triglyceride, lowdensity lipoprotein (LDL)-cholesterol, and highdensity lipoprotein (HDL)-cholesterol levels are shown in Table 2 . Total cholesterol and triglyceride levels were significantly higher in the atorvastatin group at 2D. Atorvastatin treatment significantly decreased both the total cholesterol and LDL-cholesterol levels at 24W (p < 0.01). Total cholesterol and LDL-cholesterol levels were significantly lower in the atorvastatin group compared with the control group at 24W (p < 0.05). There were no significant differences in HDL levels. 
Effects of statin treatment on plasma BNP and ANP levels
Fig . 1A shows the mean ± S.D. values of BNP level in the control and atorvastatin groups at the each sampling point. There were no significant differences between the two groups . To reduce the possible influence of variance of values, we classified the subjects into two groups by cut-off line (20 pg/mL). In the control group, the percentage of patients with a high BNP level was higher throughout the follow-up period and still 80% at 24W (Fig. 1B) . The percentage of patients with a high BNP level decreased gradually and was significantly lower at 24W compared with that at 2D in the atorvastatin group (100 to 57%, p < 0.05) (Fig. 1C ). Similar results were also observed with respect to ANP levels. There were no significant differences between the two groups in ANP values at the each sampling point ( Fig. 2A) . The percentage of the patients with a high ANP level (>40 pg/mL) was significantly decreased at 12W and 24W compared to that at 2D in the atorvastatin group (62% at 2D vs. 23% at 12W and 21% at 24W, p < 0.05 for each) (Fig. 2C ), although no significant difference existed in the control group (Fig. 2B ).
Effects of statin therapy on left ventricular ejection fraction
In Fig. 3 , each line represents the change of left ventricular ejection fraction (LVEF) in each patient. Atorvastatin significantly improved the LVEF from 58.2 ± 10.5% to 67.5 ± 9.2% at 24W (p < 0.05), while no difference was noted in the control group (Fig. 3A ). Fig. 3B shows the comparison of LVEF between the two groups at each sampling point during follow-up. The LVEF in the atorvastatin group was significantly higher than in the control group at 3W (66.0 ± 7.8% vs. 56.5 ± 11.8%; p < 0.05) and 24W (67.5 ± 9.2% vs. 59.7 ± 9.8%; p < 0.05). Fig. 4 shows changes in the left ventricular diastolic diameter (LVDd) and systolic diameter (LVDs) in each patient from 2D to 24W. The LVDd in the control group tended to increase, but not significantly. The LVDs in the atorvastatin group decreased significantly (p < 0.05), while no significant change was demonstrated in the control group.
Changes of left ventricular diameter
Correlation between cholesterol changes and LVEF and LVDs changes
To investigate if the improved cardiac function was dependent or independent of lipid-lowering, the LVEF (r = 0.098, p = 0.282) and LVDs changes (r = 0.172, p = 0.144). There were also no correlations between LDL-cholesterol changes and LVEF (r = 0.001, p = 0.952) and LVDs changes (r = 0.135, p = 0.345).
Discussion
In the present study, we showed that initiating atorvastatin therapy early after the onset of an AMI decreased plasma ANP and BNP levels and improved LVEF by reducing LVDs.
Because of the variance of values among each patient, we classified the subjects into two groups by cut-off line (20 pg/mL for BNP and 40 pg/mL for ANP). In the atorvastatin group, the percentage of patients with an elevated ANP level tended to decrease at 3W and was significantly decreased at 12W and 24W. These short-term effects of atorvastatin agree with the results of the LVEF that was improved at 3W. The effects on BNP were slower than ANP, and the percentage of patients with an elevated BNP level tended to decrease at 12W and significantly decreased at 24W with atorvastatin treatment. We have no reasonable explanation for the delayed BNP response because generally, BNP is considered a more sensitive indicator of myocardial injury. The study population, a large part of whom had relatively mild cases of AMI, may have influenced the present results.
We showed improvement in the LVEF during the follow-up period in the atorvastatin group, and decreased LVDs predominantly contributed to an increase in the LVEF. These results are consistent with previous reports that statin therapy for 3 months decreased left ventricular end-systolic volume in patients with idiopathic dilated cardiomyopathy [6] and that pitavastatin treatment for 6 months reduced LVDs in ischemic and nonischemic heart failure [7] . On the other hand, Sola et al. [8] reported that both LVDd and LVDs were decreased by atorvastatin treatment for 12 months. Taking these results into account, statin treatment may initially decrease LVDs and subsequently decrease LVDd after 6 months to improve the LVEF. Furthermore, we found that the effect of atorvastatin treatment on LVEF appeared within 3 weeks and the LVDs tended to decrease. This is the first report that shows a short duration of statin treatment (3 weeks) improved left ventricular systolic function.
The mechanisms of cardioprotective effects by statins have not been fully established. In the present study, changes in total cholesterol and LDLcholesterol levels had no correlation with changes in LVEF and LVDs. This result indicates that the cardioprotective effect of atorvastatin is independent of lipid-lowering and may be mediated by commonly called pleiotropic effects. Kodama et al. [9] reported that atorvastatin suppressed pro-inflammatory effects of vascular endothelial growth factor (VEGF) and placental growth factor (P1GF) by increasing soluble Fms-like tyrosine kinase 1 (sFlt-1), and improved LVEF at 6 months after AMI. In the present study, LVEF was significantly improved 3 weeks after the AMI onset. It is hard to explain the discrepancy of timing when atorvastatin treatment showed improvement in LVEF. Other mechanisms of anti-inflammatory effects or increased coronary flow or reduced peripheral resistance by improvement of endothelial function [10] may be associated with the early effects of atorvastatin observed in the present study.
Angiotensin-converting enzyme inhibitors [11, 12] , ␤-adrenoreceptor blockers [13] , and nitrates [14] have been shown to have beneficial effects on cardiac function after an AMI. Furthermore, clinical evidence has revealed that aldosterone blockers reduce morbidity and mortality in patients with an AMI [15, 16] . In spite of these various tools, we frequently encounter difficulties using these drugs concomitantly in the early period of an AMI because of lower blood pressure. Statins have a great advantage over other cardioprotective agents by having little impact on blood pressure.
Although PCI is the most effective therapy in the acute phase of an AMI, heart failure is still a critical complication which determines the prognosis of AMI patients. In agreement with the present results, recent reports showed that early statin treatment for AMI patients decreased the risk of congestive heart failure [17] and reduced long-term mortality [18] . These results indicate that the combination of PCI and statin treatment may be a potent and promising therapeutic strategy to improve prognosis after an AMI.
Study limitations
Among baseline characteristics, the percentage of males, serum triglyceride levels, and former smoking history were significantly different between the control and atorvastatin groups. Higher serum triglyceride levels in the statin group were expected considering patients were assigned to the control or atorvastatin groups based on the total cholesterol level. In the AMI patients with a normal cholesterol level, gender (male) and smoking history may emerge as an important indicator of risk for cardiovascular events. Considering the influence of gender differences and smoking on endothelial function [19] and atherosclerosis [20] , we cannot exclude the possible effects of these differences on the present results.
In the present study, we used the total cholesterol level to assign patients to the control or atorvastatin groups because guidelines from the Japan Atherosclerosis Society published in 2002 designated the total cholesterol level as one of the major criteria for dyslipidemia [21] . The criteria were revised in 2007, and the LDL-cholesterol level was considered a major criterion for dyslipidemia [22] . The guideline also recommended starting medication in patients with ischemic heart disease if the total cholesterol level was >200 mg/dL [21] . Therefore, we thought that 200 mg/dL was a reasonable threshold at which to start statin treatment in the present study.
